echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The fourth largest pharmaceutical company in the world was born! Second only to Pfizer, Novartis and Roche

    The fourth largest pharmaceutical company in the world was born! Second only to Pfizer, Novartis and Roche

    • Last Update: 2019-11-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [industry trends of pharmaceutical network] on November 21, BMS, a US pharmaceutical giant, announced that it had successfully acquired new base pharmaceutical with a total of US $74 billion, and it had been approved by shareholders of both sides on April 12, 2019 This is also a large-scale merger and acquisition case in the history of the pharmaceutical industry, combining two of the world's largest cancer drug manufacturers In fact, as early as January 2019, Bristol Myers Squibb announced that it would acquire the new base for a total of $74 billion (about RMB 520 billion) in cash and shares At that time, the two companies announced that the merger would bring us $2.5 billion (17.6 billion yuan) in cost savings and significantly increase profits And Bristol Myers Squibb shareholders are expected to hold about 69% of the new company's shares, while celgene shareholders are expected to hold nearly 31% Since the announcement of the acquisition, the two sides have made a series of substantive business progress, for example, the US FDA has approved inrebic (fedratinib) for the treatment of specific forms of myelofibrosis patients; the FDA has approved reblazyl (luspatercept AAMT) for the treatment of β Mediterranean adult patients with poor blood; the US and Europe have completed the regulatory filing of luspatercept and ozanimod, etc In addition, in August this year, Xinji also reached an agreement with Amgen After the merger with Bristol Myers Squibb, Xinji will spin off the psoriasis drug otezla (apremillast) globally and sell it to Amgen for $13.4 billion in cash Bristol Myers Squibb plans to prioritise the profits from the divestiture to debt reduction Now, about ten months later, Bristol Myers Squibb has successfully completed the acquisition of Xinji According to the data, Bristol Myers Squibb is a global diversified enterprise engaged in medical care and personal care products based on scientific research Its main business covers pharmaceutical products, daily consumer goods, nutrition products and medical devices According to the financial report, the net profit attributable to ordinary shareholders of Bristol Myers Squibb in 2018 is US $4.952 billion, an increase of 391.76% year on year, and the operating revenue is US $22.561 billion, an increase of 8.59% year on year New base medicine is a global biopharmaceutical company, mainly engaged in the research and development of new ways to treat cancer and immune inflammation related diseases The company is committed to R & D, innovation and design of new therapies and participating in the next generation of therapy research, aiming at the research of intracellular signal transduction pathway, balance and epigenetics of cancer and immune cell proteins, cancer and autoimmune diseases and the treatment application of regulatory cell therapy In the past five years, the sales of new base pharmaceutical products have been growing rapidly in double digits In 2017, its global product sales reached US $12.973 billion, and the first-line drug Revlimid, a blockbuster product with multiple myeloma, contributed more than 60% According to the financial report, the net profit attributable to ordinary shareholders in the annual report of the company in 2018 was USD 4.046 billion, an increase of 37.62% year on year, and the operating revenue was USD 15.281 billion, an increase of 17.52% year on year According to BMS and Xinji, the advantages of the combination include a highly complementary portfolio, franchise rights in cancer, immunity, inflammation and cardiovascular diseases, and revenue potential of more than $15 billion In addition, the combined new company will have 9 products with annual sales of more than US $1 billion, and have great growth potential in the fields of cancer treatment, immune diseases, inflammation and cardiovascular diseases The industry expects to create the fourth largest pharmaceutical company by revenue after the merger, after Pfizer, Novartis and Roche In terms of market value, the combined company may also rank in the top 10, with a total market value of about $140 billion According to another analysis, the deal brought 40% EPS growth to Bristol Myers Squibb and cost synergies of $2.5 billion.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.